SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Munch-a-Biotech Today
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (2566)4/25/2008 3:00:16 PM
From: software salesperson  Read Replies (2) of 3158
 
I once looked into the mtx dose for PA. My understanding was that liver/white blood cell issues would most likely not surface for a while, a few years at the minimum. I don’t know, but my supposition was that the RA dose would be close to the PA dose. So, I was wondering if 5/49 at the 100mg R788 dose had neutropenia requiring dose reduction at 12 weeks, whether you or BJ could judge, sans a R788 trial without mtx, how much of the neutropenia was caused by mtx vs. R788.

I’m just wondering. I have no axe to grind against rigl.

Thanks.

sales
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News